YOLFTbeta
Alzinova AB

Alzinova AB

ALZ · ST · Healthcare / Biotechnology

0.319SEK-0.00 (-0.16%)

Price History

Full chart

Market Stats

Previous Close0.3195
Open0.3205
Day Range0.30 – 0.3245
52-Week Range0.3745 – 2.28
Volume1.68M
Market Cap83.63M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.19
Dividend Yield0.00%
Beta1.08
50-Day Avg0.7797
200-Day Avg0.663

About

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. It has a research collaboration with Amsterdam University Medical Center to develop a blood based test that measures naturally occurring antibodies against toxic amyloid ß oligomers. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Tord Labuda M.Sc., Ph.D.
  • Employees7
  • HeadquartersGoCo House, Mölndal, Sweden, 431 53, Sweden
  • Websitehttps://www.alzinova.com

Leadership

  • Dr. Tord Labuda M.Sc., Ph.D.Chief Executive Officer
  • Mr. Erik KullgrenChief Financial Officer
  • Dr. Anders Sandberg Ph.D.Chief Scientific Officer · b. 1972
  • Mr. Sebastian HanssonBusiness Development Director

Financials

Income Statement

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.19M839.37K954.33K998.39K5.25M5.79M9.36M6.81M14.90M17.32M16.63M270.00K30.00K0
Growth (%)--61.67%+13.70%+4.62%+426.14%+10.24%+61.63%-27.26%+118.80%+16.27%-3.97%-98.38%-88.89%-100.00%
Cost of Revenue2.00M662.06K720.10K--4.89M-5.14M-9.35M-6.81M-14.90M-17.32M-16.63M-19.60M-16.78M-26.55M
Gross Profit193.07K177.31K234.24K998.39K10.14M10.94M18.71M6.81M14.90M17.32M33.27M19.87M16.81M26.55M
Gross Margin8.82%21.12%24.54%100.00%193.09%188.83%199.86%100.00%100.00%100.00%200.00%7360.74%56036.67%-
Operating Expense2.06M509.46K693.79K4.40M13.10M13.43M22.90M12.99M21.40M24.84M46.35M36.40M37.19M52.41M
Operating Income-1.86M-332.15K-459.55K-3.40M-2.96M-2.49M-4.19M-6.18M-6.50M-7.52M-13.09M-16.52M-20.38M-25.85M
Operating Margin-85.12%-39.57%-48.15%-341.04%-56.26%-43.00%-44.77%-90.73%-43.62%-43.41%-78.68%-6119.26%-67936.67%-
EBITDA8.69K-3.58K-11.96K-2.42K3.01K-18.13K903-6.18M-6.50M-7.52M-13.07M42.00K-20.32M-25.85M
EBITDA Margin0.40%-0.43%-1.25%-0.24%0.06%-0.31%0.01%-90.73%-43.62%-43.41%-78.57%15.56%-67723.33%-
Net Income-1.86M-335.73K-471.51K-3.41M-2.96M-2.51M-4.19M-6.20M-6.50M-7.58M-13.07M-16.48M-20.55M-26.27M
Net Income Margin-84.72%-40.00%-49.41%-341.28%-56.43%-43.31%-44.76%-91.09%-43.63%-43.79%-78.58%-6103.70%-68510.00%-
Interest Expense---08.75K18.16K13.45K12.43K91932.65K19.40K98.00K236.00K933.00K
Interest Expense % of Total Revenue---0.00%0.17%0.31%0.14%0.18%0.01%0.19%0.12%36.30%786.67%-

Balance Sheet

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.12M1.45M2.14M22.20M33.31M31.72M66.09M63.53M100.82M91.69M111.62M123.19M133.23M143.43M
Total Liabilities169.78K728.02K589.25K1.57M1.41M2.33M2.33M4.42M4.79M3.22M6.09M9.33M9.40M21.47M
Total Equity947.42K723.69K1.55M20.63M31.90M29.39M63.75M59.11M96.02M88.47M105.53M113.86M123.82M121.96M
Cash205.10K82.71K261.69K18.50M25.04M17.88M42.35M33.73M55.98M28.84M32.04M22.03M15.50M319.00K
Total Debt-400.00K400.00K770.19K800.00K800.00K800.00K800.00K800.00K800.00K800.00K800.00K800.00K800.00K
Net Debt-205.10K317.29K138.31K-17.72M-24.24M-17.08M-41.55M-32.93M-55.18M-28.04M-31.24M-21.23M-14.70M481.00K

Cash Flow

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---715.19K-3.21M-2.76M-2.13M-3.97M-3.98M-6.27M-9.82M-10.31M-15.21M-20.27M-13.03M
Investing Cash Flow---406.33K-1.42M-4.95M-5.03M-9.41M-6.89M-14.90M-17.32M-16.63M-19.60M-16.78M-26.55M
Financing Cash Flow--1.30M22.86M14.26M37.85M37.85M2.25M43.41M30.15M30.15M24.80M30.52M24.41M
Capital Expenditure0001.42M4.95M5.03M9.41M6.89M14.90M17.32M16.63M19.60M16.78M13.03M
Free Cash Flow---715.19K-4.63M-7.71M-7.16M-13.38M-10.87M-21.17M-27.14M-26.95M-34.82M-37.05M-39.58M
FCF to OCF--100.00%144.11%279.11%335.92%337.23%273.35%337.86%276.40%261.27%228.86%182.81%303.78%

Earnings

Report DateMar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018May 17, 2019Aug 28, 2019Oct 25, 2019Feb 26, 2020May 15, 2020Aug 26, 2020Oct 29, 2020Feb 25, 2021May 19, 2021Aug 26, 2021Oct 28, 2021Feb 24, 2022Apr 19, 2022Aug 25, 2022Nov 1, 2022Feb 23, 2023May 17, 2023Aug 17, 2023Nov 2, 2023Feb 28, 2024May 28, 2024Aug 22, 2024Nov 14, 2024Feb 27, 2025May 15, 2025Aug 22, 2025Nov 14, 2025Mar 25, 2026May 14, 2026Aug 21, 2026
EPS Estimate-------------------------------------0.06-----
EPS Actual-0.03-0.08-0.07-0.14-0.08-0.05-0.01-0.09-0.08-0.07-0.04-0.21-0.11-0.14-0.05-0.26-0.23-0.11-0.16-0.31-0.08-0.12-0.08-0.14-0.13-0.10-0.09-0.15-0.13-0.10-0.08-0.11-0.09-0.11-0.05-0.07-0.06-0.08-0.06-0.05-0.05-0.03
Surprise------------------------------------0.00%-----
Timing-------------Pre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----

Key Statistics & Ratios

Market Cap83.63M
Enterprise Value89.65M
Trailing P/E0.00
Forward P/E0.00
Price / Sales561.25
Price / Book0.57
EPS-0.19
Book Value0.77
Revenue (TTM)149.00K
Gross Profit (TTM)149.00K
Profit Margin0.00%
Operating Margin-17980.00%
Return on Equity-16.73%
Return on Assets-9.16%
Shares Outstanding209.07M
Shares Float171.73M
Beta1.08
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%